Researchers Submit Patent Application, "Stable Anti-Cd79b Immunoconjugate Formulations", for Approval (USPTO 20240325559).

Researchers have submitted a patent application for "Stable Anti-Cd79b Immunoconjugate Formulations" to the USPTO, aiming to address challenges in administering biologics via IV infusion bags. The patent application focuses on developing a stable pharmaceutical composition containing an anti-CD79b immunoconjugate and a surfactant to maintain stability during storage and IV administration. The formulation includes specific concentrations of the immunoconjugate, surfactant, buffering agent, and sugar to ensure stability and efficacy in treating proliferative disorders, particularly B cell proliferative disorders like lymphoma and leukemia. The patent application provides detailed information on the composition, concentration ranges, and methods for administering the pharmaceutical composition. [Extracted from the article]